MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.89% | 31.70% | 57.30% | 44.40% | 26.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.89% | 31.70% | 57.30% | 44.40% | 26.11% |
| Cost of Revenue | 3.01% | -22.02% | -2.12% | -10.27% | -20.31% |
| Gross Profit | 139.31% | 3,428.14% | 1,420.36% | 575.75% | 199.66% |
| SG&A Expenses | -15.95% | -9.10% | 5.09% | -20.22% | -31.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -133.42% | -188.75% | -190.71% | -73.98% | 22.61% |
| Total Operating Expenses | -6.81% | -17.77% | -0.59% | -16.84% | -27.25% |
| Operating Income | 70.25% | 79.75% | 58.62% | 65.32% | 57.51% |
| Income Before Tax | 23.85% | 30.51% | 46.61% | 56.64% | 67.49% |
| Income Tax Expenses | -2,940.91% | -4,511.36% | -4,511.36% | -4,511.36% | -217.86% |
| Earnings from Continuing Operations | 25.51% | 31.88% | 47.64% | 57.50% | 67.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.51% | 31.88% | 47.64% | 57.50% | 67.51% |
| EBIT | 70.25% | 79.75% | 58.62% | 65.32% | 57.51% |
| EBITDA | 83.26% | 90.97% | 66.83% | 70.99% | 58.25% |
| EPS Basic | 41.06% | 52.07% | 63.46% | 68.29% | 72.33% |
| Normalized Basic EPS | 75.10% | 83.13% | 69.41% | 72.56% | 64.92% |
| EPS Diluted | 41.06% | 52.07% | 63.46% | 68.29% | 72.33% |
| Normalized Diluted EPS | 75.10% | 83.13% | 69.41% | 72.56% | 64.92% |
| Average Basic Shares Outstanding | 22.26% | 34.64% | 43.69% | 35.91% | 23.04% |
| Average Diluted Shares Outstanding | 22.26% | 34.64% | 43.69% | 35.91% | 23.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
